EGFR and lung adenocarcinoma: Since EGFR mutations are reasonably specific for NSCLC, with frequencies as high as 58% in Asian patients with lung adenocarcinoma,19 it is rational to treat patients based on the detection of EGFR mutations in the setting of clinically suspected advanced lung cancer without pathologic diagnosis.